4-hydroxylonchocarpin and corylifol A: The potential hepatotoxic components of Psoralea corylifolia L

A review of Psoralea corylifolia L.: a valuable plant with profound biological significance

Psoralea corylifolia L. (PCL) is an annual herb of the genus Psoralea in the family Fabaceae, and its mature fruit can be used medicinally as a precious medicinal herb to tonify muscles and bones. With the deepening of research, its applications to various industries, including food, agriculture, and cosmetics, with products being developed in countries such as Vietnam, India, and Japan. A total of 321 metabolites, including coumarins, flavonoids, meroterpenes, benzofurans, and dimers, were identified in PCL. PCL and related products have demonstrated therapeutic effects, such as antiosteoporosis effects, estrogen-like effects, anti-inflammatory properties, neuroprotection, antitumor activity, and vitiligo treatment. The expression mechanisms of these pharmacological effects are closely related to the regulation of the immune system, the inhibition of oxidative stress, and the induction of apoptosis. This paper summarizes the latest research on the ethnobotany, phytochemistry, processing technology, pharmacology, and hepatotoxicity of PCL. Furthermore, bibliometric analysis was used to systematically analyze the research hotspots and trends in PCL, which have never been addressed in previous reviews of PCL. In the future, it will be necessary to focus on the active metabolites of PCL, analyze its targets and signaling pathway network to address potential toxicity and side effects in clinical applications, and further expand the potential application of PCL in medicine.

Function-oriented mechanism discovery of coumarins from Psoralea corylifolia L. in the treatment of ovariectomy-induced osteoporosis based on multi-omics analysis

ETHNOPHARMACOLOGICAL RELEVANCE

Psoraleae Fructus (Bu Gu Zhi) is the fruit of Psoralea corylifolia L. (PCL) and has been used for centuries in traditional Chinese medicine formulas to treat osteoporosis (OP). A new drug called "BX" has been developed from PCL, but its mechanism for treating OP is not yet fully understood.

AIM OF THE STUDY

To explore the mechanism of action of BX in the treatment of ovariectomy-induced OP based function-oriented multi-omics analysis of gut microbiota (GM) and metabolites.

MATERIALS AND METHODS

C57BL/6 mice were bilaterally ovariectomized to replicate the OP model. The therapeutic efficacy of BX was evaluated by bone parameters (BMD, BV/TV, Tb.N, Tb.Sp), hematoxylin and eosin (H&E) staining results, and determination of bone formation markers procollagen type Ⅰ amino-terminal peptide (PⅠNP) and bone-specific alkaline phosphatase (BALP). Serum and fecal metabolomics and high-throughput 16S rDNA sequencing were performed to evaluate effects on endogenous metabolites and GM. In addition, an enzyme-based functional correlation algorithm (EBFC) algorithm was used to investigate functional correlations between GM and metabolites.

RESULTS

BX improved OP in OVX mice by increasing BMD, BV/TV, serum PⅠNP, BALP, and improving Tb.N and Tb.Sp. A total of 59 differential metabolites were identified, and 9 metabolic pathways, including arachidonic acid metabolism, glycerophospholipid metabolism, purine metabolism, and tryptophan metabolism, were found to be involved in the progression of OP. EBFC analysis results revealed that the enzymes related to purine and tryptophan metabolism, which are from Lachnospiraceae_NK4A136_group, Blautia, Rs-E47_termite_group, UCG-009, and Clostridia_UCG-014, were identified as the intrinsic link between GM and metabolites.

CONCLUSIONS

The regulation of GM and restoration of metabolic disorders may be the mechanisms of action of BX in alleviating OP. This research provides insights into the function-oriented mechanism discovery of traditional Chinese medicine in the treatment of OP.